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Thiabendazole  (TBZ)  is widely  used  as  a  pre-planting  and  post-harvest  agricultural  fungicide  and  as  an
anthelminthic  in  humans  and  animals.  TBZ is  of toxicological  concern,  since  adverse  effects  including
nephrogenic,  hepatogenic,  teratogenic  and  neurological  effects  have  been  reported  in  mammals.  Occu-
pational  exposure  can  occur  among  agricultural  workers  and  the  general  public  may  be  environmentally
exposed  to TBZ through  the  diet.  The  metabolite  5-hydroxythiabendazole  (5-OH-TBZ)  was chosen  as
biomarker  of  exposure  to TBZ  and  a  LC/MS/MS  method  for the  quantiﬁcation  of  5-OH-TBZ  in human
urine  was  developed.  The  method  includes  enzyme  hydrolysis,  as  5-OH-TBZ  is  conjugated  to  glucuronide
and  sulphate  in  urine.  Sample  through  put  was optimised  using  96-well  plates  for sample  handling  as
well  as  for  solid  phase  extraction  (SPE).  The  method  has excellent,  within-run,  between-run  and  between-
batch  precision  between  4 and  9%.  The  limit  of  detection  (LOD)  of  0.05  and  a  limit  of  quantiﬁcation  (LOQ)
of  0.13  ng  5-OH-TBZ/mL  urine  enable  detection  in environmentally  exposed  populations.  When  applying
the  method  in  a general  Swedish  population,  52%  had  levels  above  LOD.  The  method  was  also  applied  in
one  oral  and  one  dermal  human  experimental  exposure  study  in  two individuals.  After  oral  exposure,  the
excretion  of 5-OH-TBZ  in urine  was  described  by  a  two-compartment  model  and  both  the  ﬁrst  rapid  and
the second  slower  elimination  phase  followed  ﬁrst-order  kinetics,  with  estimated  elimination  half-life
of  2 h and 9–12  h. The  recoveries  in urine  were  between  21  and  24%  of the  dose.  Dermal  exposure  was
described  by  a  one  compartment  model  and  followed  ﬁrst  order  kinetics,  with  estimated  elimination
half-life  of 9–18  h.  The  recovery  in  urine  was  1% of  the  administrated  dose  of  TBZ.  Although  these  studies
are  limited  to two individuals,  the  data  provide  new  basic  information  regarding  the toxicokinetics  of
TBZ after  oral  and  dermal  exposure.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Thiabendazole (TBZ) was introduced in the 1960s ﬁrst as an
nthelmintic in humans and animals and later also as an agricul-
ural fungicide. It is currently widely used as a fungicide, registered
ainly for pre-planting and post-harvest treatment of vegetablespotatoes) and fruits.
Agricultural workers may  be occupationally exposed to TBZ, but
tudies on exposure are missing. In the general public, there is a
Abbreviations: ADI, acceptable daily intake; b.w, body weight; CID, collision
nduced dissociation; IS, internal standard; LC/MS/MS, liquid chromatography triple
uadrupole mass spectrometry; LOD, limit of detection; LOQ, limit of quantiﬁcation;
C,  quality control; SPE, solid phase extraction; SRM, selected reaction monitoring;
BZ, thiabendazole; 5-OH-TBZ, 5-hydroxy thiabendazole.
∗ Corresponding author. Tel.: +46 46 2221645.
E-mail address: eva.ekman@med.lu.se (E. Ekman).
ttp://dx.doi.org/10.1016/j.jchromb.2014.10.003
570-0232/© 2014 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/3.0/).
potential source of exposure by residues of TBZ in food [1]. Also, for
some, medical treatment is an obvious source of exposure.
In general, mammalian toxicity is low [2]. However, humans
treated with TBZ as an anthelmintic, have experienced adverse
effects, like abdominal pain and nausea, dizziness and other cog-
nitive complaints [3–5]. Serious effects such as liver diseases have
also been reported [6] and in animal studies adverse kidney and
liver effects, as well as teratogenic and reproductive toxicity at high
doses [7–10]. TBZ is very toxic to aquatic organisms, and release
of TBZ-containing waste water into the environment is prohibited
within the EU [2].
In the risk assessment of pesticides, dermal as well as, oral and
inhalation routes of exposure should be considered [11]. How-
ever, studies on dermal uptake of TBZ are missing, a shortcoming
in view of safety control among agricultural workers. Further,
there is a need for epidemiological studies of exposure–response
relationships; in such studies an accurate exposure assessment is
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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equired. Biomarkers have many advantages in comparison with
ther methods of exposure assessment, i.e., all routes of expo-
ure are taken into account. However, for the interpretation of
xposure data, basic knowledge of the metabolic fate is impor-
ant. After human oral exposure to 1 g 14C radiolabeled TBZ, 87%
f the radioactive dose was recovered in urine [12]. Of the recov-
red dose, 38% of the metabolites was identiﬁed as conjugates of
-hydroxythiabendazole (5-OH-TBZ) and less than 1% was found as
BZ or unconjugated 5-OH-TBZ. Thus, to measure the total 5-OH-
BZ in urine samples enzymatic hydrolysis prior to measurement
s suggested.
A  biomarker of exposure should be selective and validated [13].
hus, reliable analytical methods are needed. Methods for the anal-
sis of TBZ and 5-OH-TBZ in serum, using liquid chromatography
LC) with ﬂuorescence detection [14], and in urine, using LC-UV
ave been reported [15]. However, the limit of detection, and selec-
ivity in these methods are not sufﬁcent for the use in studies of
nvironmental exposure. No mass spectrometry based methods
ave been presented previously.
The aim of this study was to develop an analytical method for
he quantiﬁcation of total 5-OH-TBZ as a biomarker of exposure to
BZ in human urine using LC/MS/MS. The method was  applied in
ne oral and one dermal human experimental exposure pilot study
n two individuals to validate 5-OH-TBZ as biomarker of exposure
nd to estimate some basic toxicokinetic data for TBZ. The method
as also applied in samples from a Swedish general population.
. Materials and method
.1. Chemicals and materials
The standards 5-OH-TBZ (10 ng/L in methanol) and TBZ were
urchased from Dr. Ehrenstorfer (Augsburg, Germany). Acetone
analytical grade ACS Reag Ph Eur) and acetic acid (glacial) were
rom Fisher Scientiﬁc (Loughborough, UK). Methanol and acetoni-
rile (hyper grade for LC-MS), ammoniumacetate (EMSURE ACS,
eag. Ph Eur), and ammonia (25%) (NH3) were from Merck (Darm-
tadt, Germany) and the enzyme -glucuronidase/arylsulfatase
rom Helix pomatia and -glucuronidase from E. coli from Roche
iagnostics Scandinavia AB (Bromma, Sweden).
Formic acid (FA) was from Sigma–Aldrich Inc. (St. Louis, MO,
SA). The IS [13C2, 15N] 5-OH-TBZ was purchased from Toronto
esearch Chemicals (North York, ON, Canada). Puriﬁed water from
 Millie-Q Integral 5 system (Millipore, Billerica, MA,  USA) was used.
Polypropylene (PP) Riplate® Squarwell (SW) 2 mL  96-well-
lates from Ritter (Schwabmünchen, Germany) were used and
ealed during long term storage in −20 ◦C with an airtight seal-
ng mat, 96 square well from Kinesis (Cambridgeshire, UK) or, for
PLC analysis, sealed with hard plastic ISOLUTE® pierceable seal-
ng capmat for leak proof closure. The different cap mats are needed
o prevent NH3 to evaporate. Solid phase extraction (SPE) column
late, ISOLUTE®-96 ENV+ 50 mg  ﬁxed well plate, was  from Biotage
Uppsala, Sweden).
.2. Instrumentation
Quantitative analysis was conducted using a triple quadrupole
inear ion trap mass spectrometer, equipped with TurboIonSpray
ource (QTRAP 5500; AB Sciex, Foster City, CA, USA) coupled to a
iquid chromatography system with two pumps (UFLCRX, Shimadzu
orporation, Kyoto, Japan). Pure nitrogen was used as curtain gas
nd collision gas. Air was used as nebuliser and auxiliary gas. The
emperature of the auxiliary gas was set at 650 ◦C and the ion
pray voltage at 5500 V. The MS/MS  analyses were carried out using
elected reaction monitoring (SRM) in positive ionisation mode. Tor. B 973 (2014) 61–67
establish the appropriate SRM conditions, standard solutions were
infused into the MS/MS  for optimisation. Collision-induced disso-
ciation (CID) of each [M+H]+ was performed and the product ions
giving the best signal to noise ratio were selected for the SRM anal-
ysis. All data acquisition and processing was performed using the
Analyst 1.6.1 application software (Applied Biosystems, Foster City,
CA, USA).
The solutions used for SPE extraction were added with a
96-multichannel pipette (Liquidator 96, Rainin pipetting 360◦)
from Rainin Instruments LLC, Mettler-Toledo International Inc.,
Greifensee, Switzerland. To accelerate the ﬂow of the liquid through
the SPE columns, positive pressure processing of the SPE-plates
using nitrogen together with a multichannel pressure processor
(CEREX 96 II multi-channel SPE) SPEware Corporation, Baldwin
Park, CA, USA was  used.
2.3. Preparation of calibration standards and quality control
samples
The 5-OH-TBZ standard was purchased dissolved. Accurately
weighed amount of IS [13C2, 15N] 5-OH-TBZ was  dissolved in
methanol. The IS and standard stock solutions were diluted further
in methanol and stored at −20 ◦C. Standard solutions were pre-
pared in duplicates. For the calibration curve, 475 L blank urine
was spiked with 25 L of the standard solutions and 25 L of the IS
solution, giving a urinary concentration between 0.05 and 100 ng 5-
OH-TBZ/mL and 5 ng IS-5-OH-TBZ/mL urine. The calibration curve
was corrected with the amount found in the chemical blank pre-
pared from Millie-Q water and thereafter treated like the other
samples. Urine blank samples and quality control (QC) samples
were obtained from healthy volunteers at our laboratory. Blank
urine samples were used for preparation of calibration curves and
zero samples. As QC-samples, two authentic urine samples were
pooled and then quantiﬁed to urinary concentrations 0.1, 1.0, 8.0
and 15 ng 5-OH-TBZ/mL urine. The QC-samples were divided into
aliquots before stored at −20 ◦C.
2.4. Sample preparation
The urine samples and QC-samples were vortex-mixed after
thawing and aliquots of 500 L were transferred into a 96-well-
plate and then 25 L of IS solution, 150 L 1 M ammonium acetate
buffer pH 6.5 and 10 L -glucuronidase/arylsulphatase obtained
from H. pomatia was  added. The plate was sealed and mixed thor-
oughly for about 1 min  before incubation. The enzyme incubation
was performed at 37 ◦C with agitation at 400 rpm for about 18 h, i.e.
overnight. After incubation, the samples were carefully mixed and
transferred to a conditioned 96-SPE-plate using the Liquidator. The
SPE-plate was conditioned in two  steps with 1 mL of methanol and
1 mL  of water. After the samples were applied, they were washed in
three steps with 1 mL  of water, 1 mL  40% methanol with 1% acetic
acid and 1 mL  acetonitrile. To elute 5-OH-TBZ and TBZ, 1 mL ace-
tonitrile containing 5% NH3 was manually added. The samples were
eluted into a freeze-cooled 96-well-plate. Thus, the evaporation
was minimised. The samples were gently mixed for 30 s and cen-
trifuged for 10 min  at 3000 × g immediately before analysis. The
plate was  stored in −20 ◦C if not analysed directly. If a sample con-
centration was above the linear range, a volume of 0.5 mL urine was
diluted with Millie-Q water until an appropriate level was  reached.
2.5. AnalysisThe separation of the analytes was carried out, using a Poroshell
120EC-C18 column (4.6 × 233 mm,  2.7 m,  Agilent Technologies,
Santa Clara, CA, USA). The two  mobile phases used consisted of
0.1% (v/v) formic acid in water (mobile phase A) and 0.1% (v/v)
E. Ekman et al. / J. Chromatog
Table  1
Summary of the SRM transitions for 5-OH-TBZ and internal standard used in the
LC/MS/MS analysis.
Compound Transitions (Da) Collision energy (V)
Quantiﬁer ions
5-OH-TBZ 218.0 → 191.2 36
[13C2][15N] 5-OH-TBZ 221.0 → 194.0 35
Qualiﬁer ions
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of TBZ in the orange juice were 2.85 mg  and 3.75 mg  for the female5-OH-TBZ 218.0 → 147.0 45
[13C2][15N] 5-OH-TBZ 221.0 → 150.0 45
ormic acid in methanol (mobile phase B). An aliquot of 3.0 L of
he sample was  injected on the column. The separation started with
socratic elution with 30% of mobile phase B for 1.0 min  followed by
 linear gradient of mobile phase B to 84% in 2.5 min, during which
he analytes eluted. The column was washed with 95% mobile phase
 during 1.0 min  and then equilibrated with 30% mobile phase B
uring 1.5 min. Post-column, the efﬂuent was diverted into the MS
etween 1.0 and 4.0 min. The total analytical run time per sam-
le, including equilibration time, was 6.5 min. The ﬂow rate was
.7 mL/min and the column was maintained at 40 ◦C. The LC/MS/MS
nalysis was performed using SRM transitions. The quantiﬁer- and
ualiﬁer-ions for 5-OH-TBZ and the IS are tabulated in Table 1. All
amples were prepared in duplicates and analysed by single injec-
ions. Concentrations were determined by peak area ratios between
nalyte and IS. All values were corrected for the chemical blank.
.6. Test of deconjugation by enzyme hydrolysis
The enzymes -glucuronidase/arylsulfatase and -
lucuronidase were tested regarding hydrolysis of the 5-OH-TBZ
onjugates. The described analytical method was used to analyse
wenty authentic samples, ten from each volunteer participating
n the oral and dermal exposure studies described below, either
ith 10 L -glucuronidase/arylsulfatase or with 20 L of the
-glucuronidase enzyme. The concentration of 5-OH-TBZ was
etermined for each sample. The ratios were then calculated.
To determine an appropriate time for enzyme incubation, a
ooled authentic urine sample was used: from each volunteer and
tudy one sample was pooled. Aliquots from this sample were
repared in duplicates for nine time points between 0 and 48 h.
he incubation starting point was scheduled for each aliquot so
hat enzyme incubation was completed at the same time, for
ll aliquots, and SPE sample preparation was performed for the
liquots together. The zero-sample aliquot was added with enzyme
ust before it was applied to the SPE-column. Then, sample prepa-
ation and analysis were performed according to the method. The
tandards and QC-samples were incubated for 18 h.
.7. Validation of the analytical method
To assess limit of detection (LOD) and limit of quantiﬁcation
LOQ) in urine matrix, seven blank authentic urine samples were
sed. LOD and LOQ were determined as the mean level of the peak
rea concentration at the same retention time as 5-OH-TBZ, plus
hree and ten times the standard deviation, respectively [16].
The linear range of the calibration curve was determined from
en concentration levels 0.1, 0.3, 0.5, 1.3, 2.5, 5.0, 10, 20, 50 and
00 ng 5-OH-TBZ/mL urine. The equation of the curve was calcu-
ated by linear regression and the correlation coefﬁcient (r) was
sed as a measure of the ﬁt of the curve.The precision of the method was determined using three dif-
erent approaches, within-run, between-run and between-batch
recision. The precision was calculated as the coefﬁcient of varia-
ion (CV) of repeated measurements. The within-run precision wasr. B 973 (2014) 61–67 63
obtained from spiked urine at three concentration levels 0.1, 5.0
and 50 ng 5-OH-TBZ/mL urine. Each level was  spiked in ten consec-
utive samples and prepared in one sample batch during one day.
The mean concentrations at the three concentration levels were
calculated.
The between-run precision was determined by including dupli-
cates of the four QC-samples, containing 0.1, 1.0, 8.0 and 15 ng
5-OH-TBZ/mL urine, in seven analytical sample batches. The QC-
samples are authentic urine samples. The batches were prepared
and analysed on separate days during a period of four months. Thus,
the standard deviation was calculated from fourteen individual
results.
A between-batch precision of the method was determined by
analysis of 110 urine samples collected in the dermal and oral
exposure studies (see below). Each urine sample was divided into
two aliquots which were then subjected to the entire analytical
procedure. The samples were prepared and analysed in separate
analytical batches and on different days. The CV was calculated
from the differences between the duplicate samples as previously
described [17].
The signal of the IS was used to determine the matrix effect. The
ratio between the mean peak area of the IS in the chemical blanks
(n = 6) and the mean peak area of the IS in authentic urine samples
(n = 80) in an analytical batch was  calculated. The geometric mean
of the matrix ratio was calculated for two analytical batches.
The recovery of 5-OH-TBZ after SPE extraction was  determined
by comparing obtained concentrations in two sets of blank urine
samples, spiked to a ﬁnal concentration of 20 ng 5-OH-TBZ/mL.
One set of samples was  spiked before applied to the SPE columns.
The other set of samples were also applied to the SPE columns but
spiked after they had eluted. Addition of IS was  made to all samples
after they were eluted from the SPE columns. The urine samples
spiked after eluting from the SPE columns were set as 100%. The
recovery was  calculated for three spiked blank urine samples.
The stability of the 5-OH-TBZ standard solutions in methanol
was investigated by reanalysis after storage at −20 ◦C for 12 months
and the authentic samples after storage at −20 ◦C for 5 months.
2.8. Ethical approval
These studies and the investigation of environmental expo-
sure to TBZ in the general population in Sweden were ethically
approved by The Regional Ethical Review Board in Lund, Lund
University, Sweden (Dnr463/2005; Dnr2010/41; Dnr2010/465 and
Dnr2013/6).
2.9. Human exposure studies
Two  healthy volunteers, one female (age 67; weight 57 kg) and
one male (age 42; weight 75 kg) had given their written informed
consent to participate in the experimental studies. They minimised
the intake of conventionally grown food a few days before as well
as during the study.
2.9.1. Oral exposure study
The two  healthy volunteers received one single oral dose corre-
sponding to 50% of the accepted daily intake (ADI) of TBZ. The ADI
for TBZ suggested by the European Union is 0.1 mg/kg/day [18]. The
TBZ was  dissolved in acetone to a concentration of 2.5 mg/mL and
was then added to 250 mL  organic orange juice. The ﬁnal amountsand male, respectively. The ﬁrst urine sample was  collected imme-
diately prior to the exposure. After exposure urine was  voided in
1 h intervals for the ﬁrst 8 h. Then, all urine voided, ad libitum for 4
days was  collected.
6 matogr. B 973 (2014) 61–67
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Fig. 1. LC/MS/MS SRM chromatogram showing (a) urinary blank, transition
218.0–191.2 Da (b) LOD in a urine sample spiked to a of 0.05 ng 5-OH-TBZ/mL urine,4 E. Ekman et al. / J. Chro
.9.2. Dermal exposure study
The dermal study was performed twelve weeks before the oral
tudy. TBZ was administrated topically on an area of 75 cm2 of the
nner forearm of the two volunteers. The dose of TBZ corresponded
o 30% and 25% of the ADI. An accurately weighed amount was
issolved in 6 mL  of acetone and a volume of 600 L containing
.75 mg  was administrated to the female and 640 L containing
.88 mg  to the male volunteer. After administration, the vehicle
vaporated to dryness and then the skin was occluded with alu-
inium foil. After 8 h of exposure, the remainder of the dose was
iped off with acetone, and the exposed area washed with soap
nd water. The ﬁrst urine sample was collected immediately prior
o the exposure. After exposure urine was voided in 2 h intervals
or the ﬁrst 12 h. Then, all urine voided, ad libitum for 6–7 days was
ollected.
.10. Sample collection and adjustments for urinary dilution
The samples collected in the two studies were stored at −20 ◦C
ntil analysis. Sample volume was determined and creatinine and
ensity were determined in all samples to adjust for the uri-
ary dilution. Creatinine was analysed with an enzymatic method
19] and density with a hand refractometer. The concentration
djusted for urinary density, Cd, was calculated according to Cd = C
observed) × (1.016 − 1)/(-1), where C (observed) is the obtained
oncentration in the urine sample,  is the measured speciﬁc den-
ity and 1.016 was used as the average reference urine density
20].
.11. Calculation of half-lives
The half-life (t1/2) of the elimination in urine was estimated from
he slope of the curve in the natural logarithm linear (ln-linear)
oncentration versus time plot, where time is given as the mid  time
oints between two sample collection time points.
.12. Application of the analytical method in an environmental
xposure study
Spot urine samples (n = 285) were collected from a general pop-
lation in Sweden and the analytical method presented above was
pplied to determine 5-OH-TBZ. The population consisted mainly
f men  and women, living and working in cities or the countryside
n the south of Sweden.
. Results and discussion
.1. Mass spectrometry and chromatography
A method for the analysis of 5-OH-TBZ in human urine using
PE and LC/MS/MS was developed. A large number of samples can
fﬁciently be analysed with the analytical method, due to the use of
6-well plates throughout the sample preparation and LC/MS/MS
nalysis. The chosen analytical column provided consistent and
eproducible chromatography and retained 5-OH-TBZ with stable
etention times and good separation (supplementary data Fig. S1).
oth 5-OH-TBZ and the IS showed an excellent sensitivity in ESI
nd positive ion mode. The transition giving the best to noise ratio
ignal was chosen as the quantiﬁer ion for 5-OH-TBZ. A second SRM
as chosen as a qualiﬁer ion to strengthen the identity of the ana-
yte. The transitions and optimum collision energies are tabulated
n Table 1.transition 218.0–191.2 Da. (c) Internal standard spiked to 5 ng/mL urine, transition
221.0–194.0 Da. Retention time of 5-OH-TBZ and IS is 5.2 min.
3.2. Deconjugation by enzyme hydrolysis
When the enzymes -glucuronidase/arylsulfatase and -
glucuronidase were tested regarding hydrolysis of the 5-OH-TBZ
conjugates, higher concentrations of 5-OH-TBZ were obtained
when -glucuronidase/arylsulfatase was used to hydrolyse the
authentic urine samples. The concentrations increased about four
times and almost two times in urine samples from the female and
male volunteer, respectively (supplementary data Table S1). There
seems to be differences between the two  subjects regarding the
level of conjugation; these results agree with earlier ﬁndings [12].
The optimal time for enzyme incubation was  found to be 18 h
(supplementary data Fig. S2).
3.3. Validation of the analytical method
The LOD was found to be 0.05 ng/mL and the LOQ  0.13 ng/mL.
Chromatograms of a urine blank (a), a urine sample at LOD (b), and
of the IS (c) are shown in Fig. 1. The LOD in urine is sufﬁciently low
for the measurement of environmental human exposure.
The obtained calibration curves in the range 0.13–100 ng 5-OH-
TBZ/mL urine showed excellent linearity with r = 0.997, a slope of
0.278 ± 0.015 (CV of 6.9%) and an intercept of 0.0395 ± 0.046 (CV of
14.7%) at 95% conﬁdence level (n = 6).
The within-run, between-run and between-batch precisions are
presented in Table 2.
The obtained concentrations at three concentration levels for
spiked samples are shown in Table 2.
The assessment of the matrix effect was performed using [13C,
15N ] 5-OH-TBZ which co-elutes with 5-OH-TBZ [21]. The geomet-2
ric mean of the ratio between the IS in the chemical blanks and
the IS in authentic urine samples was  0.99. The minor matrix effect
probably is explained by the use of SPE, the use of a [13C, 15N2] IS
E. Ekman et al. / J. Chromatogr. B 973 (2014) 61–67 65
Table  2
Precision of the method at different concentration levels. The within-run precision was calculated from spiked urine samples and the between-run and batch precision from
authentic urine samples.
5-OH-TBZ concentration (ng/mL) n Mean obtained 5-OH-TBZ concentration (ng/mL) CV (%)
Within-run precision 0.13 10 0.14 7.0
5.0  10 5.0 5.0
50  10 47 3.6
Between-run precision 0.1 14 0.2 7.8
1.0  14 1.2 7.7
8.0  14 7.9 7.5
15  14 16 6.8
Between batch precision Range 0.1–64 110 8.2 8.6
Table 3
Estimated half-life of 5-OH-TBZ and conjugates in urine of the two  volunteers orally exposed to TBZ. The dose was 0.05 mg TBZ/kg of b.w (50% of ADI) for both volunteers.
For  the calculation values after 101 h for the female and 90 h for the male were excluded due to levels below LOD.
Oral route a,bt½ (h) creatinine a,bt½ (h) density a,bt½ (h) unadjusted cCmax (nmol/mmol creatinine) TCmax (h)
Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2
Female 2 12 2 12 2 12 2385 1
Male  2 9 1 9 1 9 1729 1
n the n
and 0.
a
f
f
f
f
3
w
t
C
e
b
f
T
i
F
a
i
da The half-life of elimination (t½) in urine estimated from the slope of the curve i
b Correlation coefﬁcient (r) for the regression line of adjusted t½ were 0.94–0.98 
c Cmax urinary concentration creatinine adjusted values.
nd the analytical column, giving a good separation of the analyte
rom the matrix.
The recovery in spiked urine determined after SPE elution was
ound to be 100.3% (n = 3).
The standard solutions of 5-OH-TBZ dissolved in methanol were
ound to be stable for 12 months and the authentic urine samples
or at least 5 months when stored at −20 ◦C.
.4. Oral exposure to TBZ
In urine collected before the exposure, the 5-OH-TBZ levels
ere below LOD in both volunteers. After the oral exposure to TBZ,
he urinary levels of 5-OH-TBZ increased rapidly and the urinary
max was reached after 1 h, see Table 3 and Fig. 2a. The urinary
limination can be described by a two-compartment model and
oth the ﬁrst rapid and the second slower elimination phase
ollowed ﬁrst-order kinetics; see the excretion curve in Fig. 3a.
he half-lives of 5-OH-TBZ with correlation coefﬁcients are shown
n Table 3. The ﬁrst rapid phase was found to be only 2 h. This
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short half-life of 5-OH-TBZ (Table 3) limits its use as a biomarker
and when collecting samples for biomonitoring, the toxicokinetics
should be considered [22].
In chromatograms from the oral study, two small peaks with
the same transitions as 5-OH-TBZ eluting close to the 5-OH-TBZ
peak was  observed (supplementary data Fig. S1). Thus, samples
were screened for other metabolites using a compound-speciﬁc,
predicted SRM/Information-Dependent Acquisition method (sup-
plementary data Figs. S3 and S4).
The main metabolite was  5-OH-TBZ with glucuronide and sul-
phate conjugation. Other minor metabolites were OH-TBZ isomers,
di-hydroxy-TBZ and TBZ. The metabolic speciﬁcity was  conﬁrmed
since the concentrations increased after exposure to TBZ and
decreased as the metabolites were rapidly excreted in the urine
(supplementary data Fig. S3).
The amount of TBZ recovered in the study samples, was
quantiﬁed and found to be less than 0.05% with regard to the admin-
istrated dose in both volunteers. Hence, TBZ was not included in the
validation of the method.
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Fig. 3. Semi logarithmic urinary elimination curves of 5-OH-TBZ for the female and male volunteer after oral (a) and dermal (b) exposure to TBZ. The oral dose corresponded
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In urine, the total recovery, measured as 5-OH-TBZ, was  found
o be 21–24% of the dose of TBZ. Of the recovered dose, 96% was
ound within 24 h. In an earlier study of oral exposure to 14C-TBZ in
uman volunteers, 87% of the radioactivity was found in urine, of
hich 38% was recovered as 5-OH-TBZ conjugates, after 5 days [12].
he difference in uptake of TBZ may  be due to the difference in doses
dministrated (3 mg versus 1 g) or that the dosage form (solution
ersus suspension) to administrate the substance, differed. An oral
tudy in mice has shown that the vehicle has great inﬂuence on the
ptake of TBZ. When the mice were given 14C ring radiolabeled TBZ
n olive oil, instead of aqueous solution, TBZ was absorbed 12 times
aster and the plasma levels became 5 times higher [23]. The solu-
ility of TBZ may  be the dependent factor. Moreover, metabolites
ot found by the analytical method are likely to be formed; since the
enzene ring in TBZ can undergo ring cleavage and, sulfoxidation
as also been suggested [12].
.5. Dermal exposure to TBZ
Before the experimental exposure, the 5-OH-TBZ levels in urine
ere below LOD in both volunteers. The limited solubility of TBZ
n acetone and the limited volume possible to disperse evenly
n the application site resulted in a lower dose than in the oral
tudy above. After the dermal exposure of TBZ, the urinary lev-
ls increased slowly. The urinary Cmax was reached after 13 h in
oth volunteers compared to 1 h by the oral route (Table 4). After
 h, the level of 5-OH-TBZ in the female urine reached a bal-
nce between absorption and elimination, followed by a plateau
Fig. 2b). No plateau was seen in the male volunteer. The urinary
limination of 5-OH-TBZ seemed to follow ﬁrst-order kinetics and
 one-compartment model (Fig. 3b). Also, in other studies of dermal
able 4
stimated half-life of 5-OH-TBZ and conjugates in urine for the two  volunteers dermally e
f  b.w (ca 25% of ADI 0.1 mg/kg of b.w) for the female and male respectively. For the calcu
evels  below LOD.
Dermal route a,bt½ (h) creatinine a,bt½ (h) density a,b
Female 18 19 20
Male  9 9 10
a The half-life of elimination (t½) in urine estimated from the slope of the curve in the n
b Correlation coefﬁcient (r) for the regression line of adjusted t½ were 0.94–0.98 and 0.
c Cmax urinary concentration creatinine adjusted values.onded to 25% of the ADI. The half-life of elimination (t½) in urine is estimated from
inine adjusted urinary levels (nmol/mmol creatinine) were plotted versus the mid
exposure to pesticides in humans, a plateau in the urinary excre-
tion curve has been observed [24–29]. After 13 h, the levels started
to decrease in both volunteers, probably reﬂecting the end of expo-
sure. If there is a ﬁrst rapid elimination phase it was not observed,
probably obscured by the absorption phase. The dermal half-life is
within the same range as that of the second slower phase in the
oral study (Tables 3 and 4).
Of the administrated dermal dose, the total recovery of 5-OH-
TBZ in urine was  1% for both volunteers. The results indicate a low
uptake of TBZ. Acetone was chosen as vehicle, because of its ability
to dissolve TBZ and because it is commonly used in dermal experi-
mental exposure studies. The choice of vehicle and use of occlusion
may  affect the absorption. The permeability of the skin can be
increased by occlusion through increased hydration and temper-
ature of the skin. Also the washing after exposure has been shown
to enhance the dermal absorption [11]. The inner forearm was  cho-
sen as site of exposure as it is the most commonly used anatomic
site in dermal experimental exposure studies [28,30]. However, it
has been shown that the forehead and the neck are more permeable
than the forearm. Thus, the absorption is probably higher, if other
more permeable areas of the body are exposed [31]. This should be
considered in studies of exposure and effect.
The toxicokinetic proﬁles were different between the oral and
dermal administration routes. This may  be because the uptake is
both slower and lower in the dermal experiment. After dermal
uptake, the substance enters the blood directly, i.e., the whole sys-
tem, without passing the liver ﬁrst, as it does when entering via the
gastro intestinal tract. Moreover, the toxicokinetic proﬁles seemed
to differ between the two  individuals in the dermal study. This is
not surprising, since it is well known that xenobiotic metabolism
and excretion kinetics vary greatly depending on, i.e., age, sex, and
activity level [11].
xposed to TBZ for 8 h on an area of 75 cm2. The dose was 0.030 and 0.025 mg TBZ/kg
lation values after 160 h for the female and 91 h for the male were excluded due to
t½ (h) unadjusted cCmax (nmol/mmol creatinine) TCmax (h)
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 17 13
atural logarithm–linear concentration versus mid time plot.
90–0.94 for unadjusted.
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ticide Residues (JMPR) through 2010, http://www.who.int/foodsafety/chem/E. Ekman et al. / J. Chro
.6. Adjustments for urinary dilution
The toxicokinetic data in this study indicate that an adjust-
ent for the urinary dilution should be recommended and that
djustment for creatinine rather than for density should be applied.
owever, creatinine levels are affected by several factors (such as
ender, age, muscle mass, and meat consumption) and when com-
aring individuals, groups or populations of both sexes and various
ges, with large differences in muscle mass and meat intake, density
djustment may  be the best choice.
.7. Application of the analytical method in an environmental
xposure study
Sample concentrations in the population samples ranged from
LOD to 33 ng 5-OH-TBZ/mL urine and 52% were above the LOD.
he median was 0.05 ng/mL and the 90th percentile was 1.6 ng/mL.
The between-run precisions determined from QC-samples were
V = 4.9% at 1 ng/mL (n = 21) CV = 3.9% at 5 ng/mL (n = 21) and
V = 2.7% at 10 ng/mL (n = 21). The samples were prepared and ana-
ysed during 4 months. Thus, the method is applicable for running
arge sample batches. More detailed data from this study will be
ublished elsewhere.
. Conclusions
The metabolite 5-OH-TBZ was used as a biomarker of exposure
o TBZ and a LC/MS/MS method for the quantiﬁcation of 5-OH-TBZ
n human urine was developed. The sample through put is high as
ll sample preparation is performed in 96-well plates.
The biomarker is conjugated to glucuronide and sulphates in
rine. Thus enzyme hydrolysis using glucuronidase/arylsulfatase
s suggested.
The method has excellent precision and a low LOD which
nables detection of 5-OH-TBZ in environmentally exposed popula-
ions. When applying the method in a general Swedish population,
2% had concentration levels above LOD.
The method was applied in one oral and one dermal human
xperimental exposure study in two individuals. After oral expo-
ure to TBZ, 21–24% was recovered as 5-OH-TBZ in urine, which
as excreted in two phases with a rapid elimination half-life of 2 h
nd a slower of 9–12 h. Moreover, 96%, of the recovered dose was
ound within 24 h. For a correct exposure assessment of TBZ, the
ast elimination requires consideration of the time of sampling.
After dermal exposure to TBZ, 1% was recovered as 5-OH-TBZ in
rine with an elimination half-life of 9–18 h. Although these studies
re limited to two individuals, the data provide new information
egarding the toxicokinetics of TBZ after oral and dermal exposure
nd will make the interpretation of the biomarker levels and, thus,
isk assessment for TBZ easier.
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